account_id none on file
legal_name Regencell Bioscience Holdings Ltd
ticker RGC
cik 1829667
domain regencellbioscience.com
linkedin_company_url https://www.linkedin.com/company/74734636/admin/feed/posts/
entry_point_account_id none on file
name Regencell Bioscience Holdings Limited
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 7 executives 3 family 0
why_nownone on file
callsnone on file
filings
Future research and development expenses will include supplies and medication and travel expenses for the research and development personnel that we plan to hire and treatment costs in connection with conducting research studies.
filing / Oct 31, 2025 / receipt
These actions include pursuing additional cost savings initiatives and seeking additional financing in both public and private markets.
filing / Oct 31, 2025 / receipt
30, 2025 and 2024, we entered into agreements to lease usage of office space and staff quarters with third parties. The leases were for
filing / Oct 31, 2025 / receipt
agreement for the office space on August 9, 2021. The tenancy agreement was renewed during the year ended June 30, 2025 and commenced
filing / Oct 31, 2025 / receipt
Yat-Gai Au | 53 | Chairman, Director and Chief Executive Officer
filing / Oct 31, 2025 / receipt
James Wai Hong Chung | 48 | Director, Chief Operating Officer and Chief Strategy Officer
filing / Oct 31, 2025 / receipt
Yat-Pui Au | 51 | Chief Business Officer
filing / Oct 31, 2025 / receipt
executives
| James Wai Hong Chung | Director, Chief Operating Officer and Chief Strategy Officer | - | receipt |
| Yat-Gai Au | Chairman, Director and Chief Executive Officer | - | receipt |
| Yat-Pui Au | Chief Business Officer | - | receipt |
familynone on file
upcoming
| 2026-10-30 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug regencell-bioscience-holdings-limited
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$